A message to the Australian MG community and in particular to patients in NSW from Associate Professor Stephen Reddel.

 

I am writing to let you know that I, Steve Reddel, is taking part as a Principal Investigator in a study for patients with generalized Myasthenia Gravis (gMG). The study is sponsored by Novartis.

The study is a multicentre, double-blind, placebo-controlled phase III study of an oral medication in generalised myasthenia gravis patients with ACHR+ antibodies.

The key criteria for this study are:

  • Adult patients with generalized Myasthenia Gravis (age 18-75 years)
  • MG-ADL score ≥ 6, with ≥ 50% of the total score due to non-ocular symptoms
  • Participants receiving at least one of the following treatments for gMG for ≥ 6 months prior to baseline:
  • just one NSIST; or
  • two or more NSISTs; or
  • on frequent (at least quarterly) plasmapheresis, plasma exchange, or intravenous immunoglobulin to control symptoms despite treatment with steroids and NSISTs; or
  • one of the following gMG treatments: • a FcRN antagonist approved for gMG • rituximab • other approved gMG therapies excluding complement inhibitors

Note: Non-steroidal immunosuppressive therapies (NSIST) include azathioprine, mycophenolate mofetil, methotrexate, cyclosporine or tacrolimus.

Interested in learning more?

Please contact the Study Coordinator, Marinda Taha, on (02) 9351 0704 or email marinda.taha@sydney.edu.au if interested and you would like to know more

Myasthenia Gravis | A message to the Australian MG community and in particular to patients in NSW from Associate Professor Stephen Reddel.Myasthenia Gravis | A message to the Australian MG community and in particular to patients in NSW from Associate Professor Stephen Reddel.Myasthenia Gravis | A message to the Australian MG community and in particular to patients in NSW from Associate Professor Stephen Reddel.